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posttransplant in the failed Fontan physiology patients might be
due to various reasons.
First, an accurate determination of pulmonary vascular resis-
tance is difficult in the failed Fontan patient population because of
methodological inaccuracies that are implicit in the use of assumed
oxygen consumption. Pretransplant pulmonary hypertension even
in this modern era has consistently been a risk factor for poor
outcomes.
Second, in our experience cardiac cirrhosis of the liver can occur
especially in adults with failed Fontan physiology. Cardiac cirrho-
sis is variably encountered in adults with long-standing right heart
failure and can be insidiously present and difficult to diagnose in
the post-Fontan population owing to overlapping symptoms and
signs attributable to the failed Fontan state, such as ascites, pleural
effusions, and hypoproteinemia (4). Abdominal imaging studies
such as computed tomography and ultrasound are useful in making
the diagnosis by demonstrating a nodular liver. In selected cases,
liver biopsy may be needed because the outcome of heart trans-
plantation in patients with heart failure and dysfunction due to
passive congestion of the liver is best determined by the extent of
hepatic fibrosis demonstrated by histology (5).
Moreover, patients with significant cirrhosis have abnormal
coagulation profiles, are prone to infections, and can suffer from
hepatic decompensation postoperatively, thus adversely impacting
survival following heart transplantation. It is therefore important
to recognize the concept of cardiac cirrhosis and seek it in the
failed Fontan patient who is being considered for heart transplan-
tation. This may enable not only risk stratification but also, in
severe cases, consideration of aggressive approaches such as com-
bined heart and liver transplantation to help improve posttrans-
plant survival in these high-risk patients.
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REPLY
We appreciate the thoughtful comments from Drs. Pereira and
Shirali on our recent article (1) and would like to take this
opportunity to respond.
The power to detect significant differences in posttransplant
survival between the Fontan patients and other etiologies was
limited by the small number of Fontan patients (n  24), and
further subanalyses by type of surgery and era of transplant were
not feasible. Congenital heart disease has consistently been iden-
tified as a risk factor for one-year mortality according to reports of
the International Society for Heart and Lung Transplantation (2).
The majority of patients with congenital heart disease undergoing
transplantation have complex disease and single-ventricle physiol-
ogy. Similar to our data, conditional survival after one year was not
significantly different for the congenital heart disease patients
compared to others.
Pulmonary resistance is often impossible to determine in this
group of single-ventricle patients with multiple sources of
pulmonary blood flow; however, mortality from right heart
failure was not a cause of death in our series, except in the single
patient who had undergone a Fontan takedown procedure for
pulmonary hypertension. It is difficult to imagine that a patient
who is surviving, even poorly, with Fontan physiology would
have significant enough pulmonary hypertension leading to
right heart failure following implantation of a two-ventricle
heart.
Long-standing hepatic venous congestion was common
among patients in our series. The mean pretransplant pro-
thrombin time was 14.6  2 s, with a range of 11 to 18 s and
an international normalized ratio of 1.7  0.7, with a range of
1 to 2.9. There was no difference in the preoperative coagula-
tion profile among the three patients who died from hemor-
rhage and the other Fontan patients. Subtle abnormalities of
coagulation may have been present in these patients; however,
other causes of postoperative hemorrhage such as prolonged
cardiopulmonary bypass time and perfusion injury to the liver
may also have played a role.
Additional data from multicenter registries, such as the
Pediatric Heart Transplant Study Group, will soon be avail-
able that allows further risk stratification for posttransplant
outcome in these complex patients, and continued efforts to
define the criteria for transplantation are essential (3). We
appreciate the opportunity to respond to the letter by Drs.
Pereira and Shirali.
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Economic Effects of Extended
Clopidogrel Therapy—A Word of Caution
In the February 1 issue of the Journal, Cowper et al. (1) compared
the outcomes and costs of extending clopidogrel therapy (in
addition to aspirin) from one month to one year after percutaneous
coronary intervention (PCI), with withdrawal of clopidogrel after
one month. Unpublished per-protocol data from the Clopidogrel
for the Reduction of Events During Observation (CREDO) trial
(2) were used to estimate the effects of long-term clopidogrel use
on event rates in a sample of patients at the Duke Medical Center
undergoing PCI and receiving clopidogrel for only one month
after the procedure. The investigators concluded that clopidogrel
therapy for one year after PCI is economically attractive in respect
to cost per year of life saved, particularly in high-risk patients.
However, the conclusions of Cowper et al. (1) rest solely on the
assumption that clopidogrel between one month and one year after
PCI significantly reduces the incidence of myocardial infarction
(MI). The relative risk (RR) of MI was estimated to be 0.56 with
clopidogrel long-term, but the 95% confidence interval (CI) was
0.3 to 1.0, suggesting a possibility of no effect at all. Consequently,
the costs per year of life saved may actually be unlimited, as shown
in Figure 2 in the study by Cowper et al. (1). Moreover, by using
per-protocol rather than intent-to-treat data, an even distribution
of confounders produced by randomization was altered, which may
have incorrectly favored extended clopidogrel therapy. In fact, the
one-year intention-to-treat analysis of the CREDO trial did not
show a significant reduction of MI between day 0 and one year or
between one month and one year (RR reduction between day 0 to
one year, 21.7%; 95% CI 7.1% to 42.7%) (2,3). Similarly, the
observational PCI substudy of the Clopidogrel in Unstable Angina
to Prevent Recurrent Events (CURE) trial (4) did not show an
advantage of long-term clopidogrel use over placebo in terms of
death or MI beyond 30 days after PCI (RR reduction 23%; 95%
CI, 17% to 50%) (5).
An increase of major bleeding occurs when clopidogrel is added
to aspirin long-term (2,6,7), and bleeding (like MIs) may influence
prognosis adversely (8). Only the costs of bleeding, but not a
potential negative effect on life expectancy, were incorporated into
the model used by Cowper et al. (1). In addition, the low
compliance with therapy in the CREDO trial (60%) may have
obscured the true risk of severe bleedings with dual antiplatelet
therapy.
Finally, the conclusions of Cowper et al. (1) should be viewed
with caution—they seem overenthusiastic and may be incorrect.
Health economics cannot help to guide decisions on therapy when
there is no firm evidence of clinical efficacy. Combining clopi-
dogrel and aspirin long-term may actually do more harm than
good.
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Dr. Eriksson is correct in noting that our results hinge on the
ability of clopidogrel to reduce the incidence of myocardial
infarction (MI) between one month and one year after percutane-
ous coronary intervention (PCI), a point we emphasized in our
report (1). Although Dr. Eriksson is also technically correct in
pointing out that, as the confidence interval for relative risk (RR)
for MI ranged from 0.3 to 1.0, there is a possibility that
Clopidogrel has no effect on MI, we do not consider this to be a
likely scenario. The point estimate (0.56) is the best estimate of
RR. Because the Clopidogrel for the Reduction of Events During
Observation (CREDO) trial was not powered to detect differences
in individual components of the combined end point, borderline
s i g n i fi c a n c e
(p  0.05) for MI, one of the components, is not surprising.
Dr. Eriksson also expressed concern that the per-protocol
population may not have been balanced between groups with
respect to confounders, causing the analysis to favor clopidogrel
therapy. However, we found no differences between the treatment
groups in baseline clinical characteristics of per-protocol patients.
Furthermore, although the reduction in MI between one month
and one year in the intention-to-treat population was not signif-
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